Navigation Links
China Botanic Pharmaceutical Approved to Produce Water-Based Mixtures
Date:4/12/2011

HARBIN, China, April 12, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that its wholly owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd ("Renhuang"), has received official approval to produce water-based mixtures.

The Heilongjiang State Food and Drug Administration (SFDA) has recently issued a new Drug Manufacturing certificate to Renhuang which will permit it to commence production of water-based mixtures. These mixtures are compound liquids that use water as solvent and contain one or more components extracted from Chinese herbal medicine. Unlike decoction that takes long time to prepare, mixture is easy to carry, store and use.  Under the terms of its original Manufacturing Certificate, Renhuang is authorized to make granules, soft capsules, tablets (including cephalosporins), oral liquids, syrups, and hard capsules but not water-based mixtures.

Innovation in manufacturing processes that allow the introduction of new products has been an important route to China Botanic's development of its product pipeline.  It is anticipated that the approval to make water-based mixture products will allow the Company to enhance its product lineup further.

"Our new Drug Manufacturing certificate is a testament to the depth, breadth and sophistication of CBP's production capabilities," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic.  "Obtaining this approval indicates that we have obtained the highest caliber of production control.  This certificate will allow us to extend our scope of production, and broaden our range of all-natural treatments."

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:

CCG Investor Relations:China Botanic Pharmaceutical Inc.

Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact

Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162

Email: mark.collinson@ccgir.comEmail: ir@renhuang.com

Website: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email: crocker.coulson@ccgir.com
'/>"/>

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. C3i Opens Asia Language Center in Dalian, China
2. China Sky One Medical Obtains Production Licenses for Thirteen New Medical Products
3. Mindray Medical to Exhibit New Products at 65th China International Medical Equipment Fair
4. Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
5. Chinese Army Established the First Chest Pain Rescue Network in China by Using IVT mHealth System
6. Sinovac Participates in UBS Greater China Healthcare Corporate Day
7. China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing
8. China Medicine Corporation Voluntarily Withdraws Application for Nasdaq Listing
9. Varian Medical Systems to Exhibit New TrueBeam™ System for Image-Guided Radiotherapy at ChinaMed Exhibition in Beijing
10. 2011 China-Africa Brightness Action Launched in Beijing
11. China-Biotics Wins First US Customer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ... IT operations analytics and application performance monitoring (APM) solutions, has expanded its ... services providers. , According to Peter Ohrenberger, sales director at Nastel, “We’ve ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... platform, in which their iMedSecure™ comes included with each system installation. RMT’s ... images to remote participants for real-time collaboration and immediate decision-making requirements. While ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar ... non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has ... to complete regulatory submissions and fund final engineering and initial production of the ...
(Date:7/20/2017)... , ... July 20, 2017 , ... The Dermatology Clinic ... Dr. Dunbar received his BS in Biology from LSU, graduating summa cum laude. He ... Class President. After his residency in St. Louis, Dr. Dunbar moved to New York ...
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... ... A Guide to the Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 ... members who contributed to this effort through Guild collaborative teams. , Non-members may ...
Breaking Medicine News(10 mins):